The largest community of pharma leaders

Experic Welcomes Niyati Patel as the Director of Quality Assurance and Compliance

CRANBURY, N.J.–()–Experic, a contract manufacturing organization (CMO) and pharmaceutical supply service company, announces the hire of Niyati Patel as the director of quality assurance and compliance in October 2019. Patel is the latest addition to Experic’s team of seasoned industry professionals dedicated to redefining clinical and commercial drug manufacturing, packaging, and distribution services for biopharmaceutical companies worldwide.

“Niyati’s strong analytical skills and exceptional knowledge make her an excellent addition to the quality assurance department,” said Mandy Gervasio, vice president, quality assurance and compliance, at Experic. “Her quality management systems expertise complements and extends our organizational capabilities and will help facilitate Experic’s growth and ensure the organization meets regulatory and compliance requirements. We’re very pleased to have her on our team.”

Patel brings over a decade of experience in quality management system processes and requirements to her new role as well as established expertise in domestic and international regulatory compliance, product development, and design controls. Most recently she served as the associate director of quality assurance at Extremity Medical, LLC.

About Experic
Experic, a contract manufacturing organization (CMO) and pharmaceutical supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across a range of dosing and packaging formats, including tablets, pellets, capsules, and low dose dry powder inhalation. From our state-of-the-art, 45,500-square-foot Class A cGMP facility, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service. Learn more about our manufacturing and supply services at expericservices.com.

Source

Recent Articles

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.